The global proton pump inhibitors market is estimated to be valued at US$ 2.9 billion in 2023 and is projected to reach US$ 4.2 billion by 2023, exhibiting a CAGR of 4.30% during the forecast period. Proton pump inhibitors are a group of medications that reduce the production of stomach acid, used to treat conditions such as gastroesophageal reflux disease (GERD), ulcers, and Barrett’s esophagus. These drugs provide several advantages such as rapid relief from acid-related disorders and better healing rates for ulcers. The increasing prevalence of GERD and other gastrointestinal disorders has led to a growing demand for proton pump inhibitors in the market.
Market key trends:
One of the key trends driving the proton pump inhibitors market is the rising adoption of generic drugs. With the expiration of patents for branded proton pump inhibitors, generic versions have gained significant traction. Generic drugs are more cost-effective than their branded counterparts, making them accessible to a larger patient population. Moreover, the high efficacy and safety profiles of generic proton pump inhibitors have further contributed to their growing adoption. The increasing focus of pharmaceutical companies on expanding their product portfolios with generic proton pump inhibitors is expected to fuel the market growth.
The Global Proton Pump Inhibitors Market can be segmented based on the type of drug, distribution channel, and region. In terms of the type of drug, the dominating segment in the market is the omeprazole drug segment. Omeprazole is one of the most widely prescribed proton pump inhibitors and is used for treating various acid-related disorders such as gastroesophageal reflux disease (GERD) and peptic ulcers. It is dominating the market due to its proven effectiveness and affordability compared to other drugs in the market.
In terms of distribution channel, the hospital pharmacies segment dominates the proton pump inhibitors market. The dominance of this segment can be attributed to the increasing number of patients with acid-related disorders being treated in hospitals and the availability of a wide range of proton pump inhibitors in hospital pharmacies.
The global proton pump inhibitors market is expected to witness high growth, exhibiting a CAGR of 4.30% over the forecast period (2023-2030). This growth can be attributed to the increasing prevalence of GERD and other acid-related disorders worldwide. The rising adoption of proton pump inhibitors as a preferred treatment option, along with the increasing awareness among patients about these drugs, is also expected to drive market growth.
In terms of regional analysis, North America is the fastest-growing and dominating region in the proton pump inhibitors market. The high prevalence of GERD and peptic ulcers, along with the availability of advanced healthcare infrastructure and favorable reimbursement policies, are driving the market growth in this region. Europe is also a significant market for proton pump inhibitors, mainly due to the high adoption rate of these drugs and the presence of key market players.
Key players operating in the proton pump inhibitors market include AstraZeneca PLC/AB, Bayer AG, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt. Ltd, Santarus, Inc., Wyeth, LLC, Janssen Pharmaceutica, Takeda Pharmaceutical Company Limited, Sanofi S.A, Aurobindo Pharma, Perrigo Company plc, Dr. Reddy’s Laboratories, Aralez Pharmaceuticals Inc., RedHill Biopharma Ltd (ADR), and Cipla Limited. These key players dominate the market due to their strong distribution networks, extensive product portfolios, and continuous investments in research and development to introduce innovative proton pump inhibitors.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it